| The biological properties of cetuximab B Vincenzi, G Schiavon, M Silletta, D Santini, G Tonini Critical reviews in oncology/hematology 68 (2), 93-106, 2008 | 112 | 2008 |
| Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a … B Vincenzi, M Di Maio, M Silletta, L D’Onofrio, C Spoto, MC Piccirillo, ... PLoS One 10 (7), e0133488, 2015 | 51 | 2015 |
| Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome B Vincenzi, D Santini, S Galluzzo, A Russo, F Fulfaro, M Silletta, ... Clinical Cancer Research 14 (13), 4219-4224, 2008 | 51 | 2008 |
| Cell cycle alterations and lung cancer B Vincenzi, G Schiavon, M Silletta, D Santini, GM Perrone, M Di Marino, ... Histology and histopathology, 2006 | 44 | 2006 |
| Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients B Vincenzi, D Santini, A Russo, M Silletta, M Gavasci, F Battistoni, ... Annals of oncology 17 (5), 835-841, 2006 | 41 | 2006 |
| Antiangiogenic properties of metronomic chemotherapy in breast cancer G Tonini, G Schiavon, M Silletta, B Vincenzi, D Santini Future Medicine Ltd 3 (2), 183-190, 2007 | 24 | 2007 |
| Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options B Vincenzi, AM Frezza, G Schiavon, D Santini, P Dileo, M Silletta, D Delisi, ... Clinical sarcoma research 3 (1), 6, 2013 | 15 | 2013 |
| Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience B Vincenzi, M Silletta, G Schiavon, AM Frezza, R Del Vescovo, BB Zobel, ... Expert opinion on investigational drugs 22 (1), 1-7, 2013 | 14 | 2013 |
| Emerging kinase inhibitors of the treatment of gastric cancer B Vincenzi, M Imperatori, M Silletta, E Marrucci, D Santini, G Tonini Expert opinion on emerging drugs 20 (3), 479-493, 2015 | 8 | 2015 |
| Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma D Santini, R Addeo, B Vincenzi, A Calvieri, L Montella, M Silletta, ... Expert review of anticancer therapy 12 (10), 1283-1288, 2012 | 8 | 2012 |
| The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker? F Pantano, M Santoni, G Procopio, M Rizzo, R Iacovelli, C Porta, A Conti, ... PloS one 10 (4), e0120427, 2015 | 6 | 2015 |
| PML down‐regulation in soft tissue sarcomas B Vincenzi, G Perrone, D Santini, F Grosso, M Silletta, A Frezza, S Rossi, ... Journal of cellular physiology 224 (3), 644-648, 2010 | 6 | 2010 |
| Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol AC Gardini, L Faloppi, G Aprile, O Brunetti, C Caparello, J Corbelli, ... Tumori Journal 104 (6), 476-479, 2018 | 5 | 2018 |
| Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients? D Santini, B Vincenzi, O Venditti, E Dell’Aquila, A Maria Frezza, M Silletta, ... Future Oncology 9 (12), 1809-1811, 2013 | 5 | 2013 |
| Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside B Vincenzi, A Napolitano, L D'Onofrio, AM Frezza, M Silletta, O Venditti, ... Expert opinion on investigational drugs 20 (12), 1685-1705, 2011 | 5 | 2011 |
| Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS). S Ferrari, PG Casali, JY Blay, G Tonini, A Le Cesne, N Ali, V Perfetti, ... Journal of Clinical Oncology 31 (15_suppl), 10568-10568, 2013 | 4 | 2013 |
| PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline‐based first line therapy B Vincenzi, D Santini, G Schiavon, AM Frezza, M Silletta, P Crucitti, ... Journal of cellular physiology 227 (4), 1657-1662, 2012 | 4 | 2012 |
| The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies B Vincenzi, G Schiavon, M Silletta, D Santini, G Tonini Expert opinion on emerging drugs 11 (4), 665-683, 2006 | 4 | 2006 |
| Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review AC Gardini, D Santini, G Aprile, N Silvestris, E Felli, FG Foschi, G Ercolani, ... Oncotarget 8 (39), 66699, 2017 | 3 | 2017 |
| Stevens–Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitunumab F Pantano, M Silletta, A Iovieno, B Vincenzi, D Santini, S Galluzzo, ... International journal of colorectal disease 24 (10), 1247-1248, 2009 | 3 | 2009 |
